Mark Foster Appointed to Xenocor Board

Xenocor Inc., developer of the first single-use, fog-free, portable, HD Laparoscopic Imaging System, has appointed Mark Foster to its Board of Directors. 
 
“There is incredible potential in this company. Not only does the technology of Xenoscope advance the bar for laparoscopic surgery, but it also makes minimally invasive surgery more accessible. Which is good for everyone. I see every reason for the successful introduction of the Xenocope into the US market and other markets around the world,” said Foster, CEO of Trice Medical and Xenocor’s newest board member. “I look forward to working with this capable, insightful and motivated team.” 
 
A versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies, Foster will provide strategic council to augment current fundraising, production, commercialization and distribution efforts at Xenocor.
 
Foster is currently the CEO of Trice Medical, a venture-backed company that has a portfolio of products for minimally invasive diagnostic and therapeutic orthopedic procedures. In his tenure at Trice, he has acquired and integrated two companies, raised more than $60 million of debt/equity, expanded the employee base from 12 to 100 people, and drove significant increase in asset value.
 
He has held senior management positions focused on business development to include fund-raising, licensing, M&A, commercialization and supply chain initiatives at two large, public companies—Smith+Nephew plc and Boston Scientific Corp.
 
“It is clear from Mark’s many accomplishments and business acumen that he can see into the heart of a company, comprehend its potential and envision a successful road forward,” said Evan Kelso, CEO of Xenocor. “His insights are invaluable and there is no doubt we will benefit from his expertise and passion in all facets of our business.” 
 
Xenocor’s U.S. Food and Drug Administration (FDA)-cleared Xenoscope is a single–use, fog-free, high definition (HD) laparoscopic imaging system that can easily replace high-cost, inflexible legacy technology to deliver advanced quality surgical care to any location worldwide. The Xenoscope provides both clinical and financial advantages that benefit surgeons, staff, healthcare facilities and most importantly, patients. It is well-positioned to replace expensive, inflexible legacy technologies making laparoscopic surgery possible virtually anywhere.
 
Xenocor offers a suite of fog-free, single-use endoscopes for minimally invasive surgical procedures. This technology emerged from the Center for Medical Innovation at the University of Utah. The current product offerings are FDA-cleared, CE Marked and patent protected. Xenocor is a privately held corporation based in Salt Lake City, Utah.